-
Multimerization of TREM2 is impaired by Alzheimer's disease–associated variants Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-20 Hunter B. Dean, Rory A. Greer, Shan‐Zhong Yang, Daniel S. Elston, Thomas J. Brett, Erik D. Roberson, Yuhua Song
INTRODUCTIONThe immune receptor triggering receptor expressed on myeloid cells 2 (TREM2) is among the strongest genetic risk factors for Alzheimer's disease (AD) and is a therapeutic target. TREM2 multimers have been identified in crystallography and implicated in the efficacy of antibody therapeutics; however, the molecular basis for TREM2 multimerization remains poorly understood.METHODSWe used molecular
-
Multiple sclerosis in Denmark (1950–2023): mean age, sex distribution, incidence and prevalence Brain (IF 10.6) Pub Date : 2024-07-20 Rolf P Holm, Malthe F Wandall-Holm, Melinda Magyari
With rising life expectancy and advancements in disease management, we expect the multiple sclerosis population is getting older. However, evidence supporting this hypothesis remains sparse. Our study aimed to determine whether the mean age of the Danish multiple sclerosis population has increased and to analyse the developments in sex distribution, incidence, and prevalence, all of which affect age
-
Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome Acta Neuropathol. (IF 9.3) Pub Date : 2024-07-18 Amal Kasri, Elena Camporesi, Eleni Gkanatsiou, Susana Boluda, Gunnar Brinkmalm, Lev Stimmer, Junyue Ge, Jörg Hanrieder, Nicolas Villain, Charles Duyckaerts, Yannick Vermeiren, Sarah E. Pape, Gaël Nicolas, Annie Laquerrière, Peter Paul De Deyn, David Wallon, Kaj Blennow, Andre Strydom, Henrik Zetterberg, Marie-Claude Potier
-
Tau protein profiling in tauopathies: a human brain study Mol. Neurodegener. (IF 14.9) Pub Date : 2024-07-19 Juan Lantero-Rodriguez, Elena Camporesi, Laia Montoliu-Gaya, Johan Gobom, Diana Piotrowska, Maria Olsson, Irena Matečko Burmann, Bruno Becker, Ann Brinkmalm, Björn M. Burmann, Michael Perkinton, Nicholas J. Ashton, Nick C. Fox, Tammaryn Lashley, Henrik Zetterberg, Kaj Blennow, Gunnar Brinkmalm
Abnormal accumulation of misfolded and hyperphosphorylated tau protein in brain is the defining feature of several neurodegenerative diseases called tauopathies, including Alzheimer’s disease (AD). In AD, this pathological change is reflected by highly specific cerebrospinal fluid (CSF) tau biomarkers, including both phosphorylated and non-phosphorylated variants. Interestingly, despite tau pathology
-
Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-19 Daniel J. Figdore, Michael Griswold, Joshua A. Bornhorst, Jonathan Graff‐Radford, Vijay K. Ramanan, Prashanthi Vemuri, Val J. Lowe, David S. Knopman, Clifford R. Jack, Ronald C. Petersen, Alicia Algeciras‐Schimnich
INTRODUCTIONWe aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p‐tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status for implementation in clinical practice.METHODSClinical performance of plasma p‐tau217 against amyloid positron emission tomography status was evaluated in participants with mild cognitive impairment or mild dementia (n = 427)
-
Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-19 Courtney M. Kloske, Michael E. Belloy, Elizabeth E. Blue, Gregory R. Bowman, Maria C. Carrillo, Xiaoying Chen, Ornit Chiba‐Falek, Albert A. Davis, Gilbert Di Paolo, Francesca Garretti, David Gate, Lesley R. Golden, Jay W. Heinecke, Joachim Herz, Yadong Huang, Costantino Iadecola, Lance A. Johnson, Takahisa Kanekiyo, Celeste M. Karch, Anastasia Khvorova, Sascha J. Koppes‐den Hertog, Bruce T. Lamb, Paige
INTRODUCTIONThe apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid‐beta and tau pathologies but also lipid and energy metabolism, neuroinflammation, cerebral vascular health, and sex‐dependent disease manifestations. Furthermore, ancestral background may
-
Presynaptic hyperexcitability reversed by positive allosteric modulation of a GABABR epilepsy variant Brain (IF 10.6) Pub Date : 2024-07-19 Marielle Minere, Martin Mortensen, Valentina Dorovykh, Gary Warnes, Dean Nizetic, Trevor G Smart, Saad B Hannan
GABABRs are key membrane proteins that continually adapt the excitability of the nervous system. These G-protein coupled receptors are activated by the brain’s premier inhibitory neurotransmitter GABA. They are obligate heterodimers composed of GABA-binding GABABR1 and G-protein-coupling GABABR2 subunits. Recently, three variants (G693W, S695I, I705N) have been identified in the gene (GABBR2) encoding
-
Shared patterns of glial transcriptional dysregulation link Huntington’s disease and schizophrenia Brain (IF 10.6) Pub Date : 2024-07-19 Nguyen P T Huynh, Mikhail Osipovitch, Rossana Foti, Janna Bates, Benjamin Mansky, Jose C Cano, Abdellatif Benraiss, Chuntao Zhao, Q Richard Lu, Steven A Goldman
Huntington’s disease and juvenile-onset schizophrenia have long been regarded as distinct disorders. However, both manifest cell-intrinsic abnormalities in glial differentiation, with resultant astrocytic dysfunction and hypomyelination. To assess whether a common mechanism might underlie the similar glial pathology of these otherwise disparate conditions, we used comparative correlation network approaches
-
Integrating Social Work in Late‐Stage Parkinson's Care: A Multifaceted Approach Mov. Disord. (IF 7.4) Pub Date : 2024-07-19 Shijie Guo, Guang Yang
-
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R1 Mov. Disord. (IF 7.4) Pub Date : 2024-07-19 Christopher Kruse, Richard Dodel, Anette Schrag
-
Heterogeneity of CSF1R‐RD: Genes, Environment, or Both? Mov. Disord. (IF 7.4) Pub Date : 2024-07-19 Jarosław Dulski, Zbigniew K. Wszolek
-
Reply to: “Further Evidence of Cerebellar Cognitive Affective/Schmahmann Syndrome in RFC1‐Related Syndrome” Mov. Disord. (IF 7.4) Pub Date : 2024-07-19 Kathy Dujardin, Céline Tard, Emily Diglé, Virginie Herlin, Eugénie Mutez, Jean‐Baptiste Davion, Anna Wissocq, Violette Delforge, Gregory Kuchcinski, Vincent Huin
-
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both? Mov. Disord. (IF 7.4) Pub Date : 2024-07-19 Jingying Wu, Li Cao
-
-
Further Evidence of Cerebellar Cognitive Affective/Schmahmann Syndrome in RFC1‐Related Syndrome Mov. Disord. (IF 7.4) Pub Date : 2024-07-19 Ines Albajar, Pablo Iruzubieta, Myriam Barandiaran, Patricia Alves, Aurora Pujol, Edgard Verdura, Jon Equiza, Iratxe Urreta, Javier Ruiz‐Martínez, Miren Maneiro, Roberto Fernandez‐Torron, Juan Jose Poza, Elisabet Mondragón, Adolfo Lopez de Munain
-
-
-
Empowering a person‐centered long‐term care workforce Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-18 Doug Pace, Shadoworee Betts, Lillian Reda, Merle Griff, Lauren Stratton, Emily Shubeck, Lakelyn Eichenberger, Nikki Holles, Lisa Holloway, Rachel Little, Sharon McGuire, Joyce Mahoney, Cole Smith, Sam Fazio
Currently there is a crisis in the long‐term care workforce, as many workers experience poor pay, a lack of training, burnout, low quality working conditions, and physical strain, which is leading to a workforce shortage. To address this, the Alzheimer's Association Dementia Care Provider Roundtable (AADCPR) convened a panel of direct care workers to discuss and provide direction on their view of the
-
Genome‐wide meta‐analysis identifies ancestry‐specific loci for Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-18 Yi‐Jun Ge, Shi‐Dong Chen, Bang‐Sheng Wu, Ya‐Ru Zhang, Jun Wang, Xiao‐Yu He, Wei‐Shi Liu, Yi‐Lin Chen, Ya‐Nan Ou, Xue‐Ning Shen, Yu‐Yuan Huang, Yi‐Han Gan, Liu Yang, Ling‐Zhi Ma, Ya‐Hui Ma, Ke‐Liang Chen, Shu‐Fen Chen, Mei Cui, Lan Tan, Qiang Dong, Qian‐Hua Zhao, Yan‐Jiang Wang, Jian‐Ping Jia, Jin‐Tai Yu
INTRODUCTIONAlzheimer's disease (AD) is a devastating neurological disease with complex genetic etiology. Yet most known loci have only identified from the late‐onset type AD in populations of European ancestry.METHODSWe performed a two‐stage genome‐wide association study (GWAS) of AD totaling 6878 Chinese and 63,926 European individuals.RESULTSIn addition to the apolipoprotein E (APOE) locus, our
-
How many future dementia cases would be missed by a high‐risk screening program? A retrospective cohort study in a population‐based cohort Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-18 Sebastian Walsh, Lindsay Wallace, Richard Merrick, Shabina Hayat, Robert Luben, Oliver Mytton, Louise Lafortune, Carol Brayne
INTRODUCTIONRisk prediction models aim to identify those at high risk to receive targeted interventions. We aimed to identify the proportion of future dementia cases that would be missed by a high‐risk screening program.METHODSWe identified validated dementia risk prediction models from systematic reviews. We applied these to European Prospective Investigation of Cancer Norfolk, a large population‐based
-
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation Brain (IF 10.6) Pub Date : 2024-07-18 Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer
Epstein-Barr virus (EBV) infection has long been associated with the development of multiple sclerosis (MS). MS patients have elevated titers of EBV-specific antibodies in serum and show signs of CNS damage only after EBV infection. Regarding CD8+ T-cells, an elevated but ineffective response to EBV was suggested in MS patients, who present with a broader MHC-I-restricted EBV-specific T-cell receptor
-
Combined clinical, structural, and cellular studies discriminate pathogenic and benign TRPV4 variants Brain (IF 10.6) Pub Date : 2024-07-18 Sarah H Berth, Linh Vo, Do Hoon Kwon, Tiffany Grider, Yasmine S Damayanti, Gage Kosmanopoulos, Andrew Fox, Alexander R Lau, Patrice Carr, Jack K Donohue, Maya Hoke, Simone Thomas, Chafic Karim, Alex J Fay, Ethan Meltzer, Thomas O Crawford, Rachelle Gaudet, Michael E Shy, Ute A Hellmich, Seok-Yong Lee, Charlotte J Sumner, Brett A McCray
Dominant mutations in the calcium-permeable ion channel TRPV4 (transient receptor potential vanilloid 4) cause diverse and largely distinct channelopathies, including inherited forms of neuromuscular disease, skeletal dysplasias, and arthropathy. Pathogenic TRPV4 mutations cause gain of ion channel function and toxicity that can be rescued by small molecule TRPV4 antagonists in cellular and animal
-
Neuroinflammation Parallels 18F‐PI‐2620 Positron Emission Tomography Patterns in Primary 4‐Repeat Tauopathies Mov. Disord. (IF 7.4) Pub Date : 2024-07-18 Maura Malpetti, Sebastian N. Roemer, Stefanie Harris, Mattes Gross, Johannes Gnörich, Andrew Stephens, Anna Dewenter, Anna Steward, Davina Biel, Amir Dehsarvi, Fabian Wagner, Andre Müller, Norman Koglin, Endy Weidinger, Carla Palleis, Sabrina Katzdobler, Rainer Rupprecht, Robert Perneczky, Boris‐Stephan Rauchmann, Johannes Levin, Günter U. Höglinger, Matthias Brendel, Nicolai Franzmeier
BackgroundPreclinical, postmortem, and positron emission tomography (PET) imaging studies have pointed to neuroinflammation as a key pathophysiological hallmark in primary 4‐repeat (4R) tauopathies and its role in accelerating disease progression.ObjectiveWe tested whether microglial activation (1) progresses in similar spatial patterns as the primary pathology tau spreads across interconnected brain
-
Skin α‐Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease Mov. Disord. (IF 7.4) Pub Date : 2024-07-18 Mary Kate LoPiccolo, Zerui Wang, Gadi Maayan Eshed, Luca Fierro, Chanan Stauffer, Kelly Wang, Jing Zhang, Curtis Tatsuoka, Manisha Balwani, Wen‐Quan Zou, Roy N. Alcalay
BackgroundPatients with type 1 Gaucher disease (GD1) have a significantly increased risk of developing Parkinson's disease (PD).ObjectiveThe objective of this study was to evaluate skin α‐synuclein (αSyn) seeding activity as a biomarker for GD1‐related PD (GD1‐PD).MethodsThis single‐center study administered motor and cognitive examinations and questionnaires of nonmotor symptoms to adult patients
-
Suppressing UBE2N ameliorates Alzheimer's disease pathology through the clearance of amyloid beta Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-17 Chen Zhang, Qingqing Jia, Longhong Zhu, Junqi Hou, Xiang Wang, Dandan Li, Jiawei Zhang, Yiran Zhang, Su Yang, Zhuchi Tu, Xiao‐Xin Yan, Weili Yang, Shihua Li, Xiao‐Jiang Li, Peng Yin
INTRODUCTIONAging is one of the risk factors for the early onset of Alzheimer's disease (AD). We previously discovered that the age‐dependent increase in Ubiquitin Conjugating Enzyme E2 N (UBE2N) plays a role in the accumulation of misfolded proteins through K63 ubiquitination, which has been linked to AD pathogenesis. However, the impact of UBE2N on amyloid pathology and clearance has remained unknown
-
Care partner‐informed meaningful change thresholds for the Clinical Dementia Rating‐Sum of Boxes for trials of early Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-17 Claire J. Lansdall, Edmond Teng, Jerome Chague, Rohan Palanganda, Paul Delmar, Janice Smith, Jeffrey L. Cummings, Fiona McDougall
INTRODUCTIONConsensus definitions of meaningful within‐patient change (MWPC) on the Clinical Dementia Rating‐Sum of Boxes (CDR‐SB) are needed. Existing estimates use clinician‐rated anchors in clinically diagnosed Alzheimer's disease (AD) populations. Incorporating the care partner perspective offers important insights, and evaluating biomarker‐confirmed cohorts aligns estimates with ongoing trials
-
Sustained frailty remission and dementia risk in older adults: A longitudinal study Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-17 Shuomin Wang, Qianyuan Li, Shanshan Wang, Chongmei Huang, Qian‐Li Xue, Sarah L. Szanton, Minhui Liu
INTRODUCTIONPhysical frailty is reversible, but little is known about the sustainability of frailty remission and its impact on dementia.METHODSData were derived from the National Health and Aging Trends Study (NHATS) (2011 to 2021). Physical frailty was assessed using the Fried frailty phenotype, and frailty transition patterns across three waves were defined. The relationship of sustained frailty
-
Disentangling genetic risks for development and progression of Alzheimer’s disease Brain (IF 10.6) Pub Date : 2024-07-17 Niklas Mattsson-Carlgren
This scientific commentary refers to ‘Towards cascading genetic risk in Alzheimer’s disease’ by Altmann et al. (https://doi.org/10.1093/brain/awae176).
-
Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma Acta Neuropathol. (IF 9.3) Pub Date : 2024-07-16 Timothy E. Richardson, Jamie M. Walker, Dolores Hambardzumyan, Steven Brem, Kimmo J. Hatanpaa, Mariano S. Viapiano, Balagopal Pai, Melissa Umphlett, Oren J. Becher, Matija Snuderl, Samuel K. McBrayer, Kalil G. Abdullah, Nadejda M. Tsankova
-
Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy Acta Neuropathol. (IF 9.3) Pub Date : 2024-07-16 Marie-Therese Holzer, Akinori Uruha, Andreas Roos, Andreas Hentschel, Anne Schänzer, Joachim Weis, Kristl G. Claeys, Benedikt Schoser, Federica Montagnese, Hans-Hilmar Goebel, Melanie Huber, Sarah Léonard-Louis, Ina Kötter, Nathalie Streichenberger, Laure Gallay, Olivier Benveniste, Udo Schneider, Corinna Preusse, Martin Krusche, Werner Stenzel
-
Prospects and challenges in using neuronal extracellular vesicles in biomarker research Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-16 Debora A. S. Rocha, Luis E. Santos, Pedro B. Da Fonseca, Fernanda G. De Felice
Extracellular vesicles (EVs) hold promise as a source of disease biomarkers. The diverse molecular cargo of EVs can potentially indicate the status of their tissue of origin, even against the complex background of whole plasma. The main tools currently available for assessing biomarkers of brain health include brain imaging and analysis of the cerebrospinal fluid of patients. Given the costs and difficulties
-
The rich information hidden in misspoken discourse Brain (IF 10.6) Pub Date : 2024-07-16 Argye E Hillis
This scientific commentary refers to ‘Artificial intelligence classifies primary progressive aphasia from connected speech’ by Rezaii et al. (https://doi.org/10.1093/brain/awae196).
-
Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer’s disease Brain (IF 10.6) Pub Date : 2024-07-16 Johanna Appleton, Quentin Finn, Paolo Zanotti-Fregonara, Meixiang Yu, Alireza Faridar, Mohammad O Nakawah, Carlos Zarate, Maria Carrillo, Bradford C Dickerson, Gil Rabinovici, Liana G Apostolova, Joseph C Masdeu, Belen Pascual
Brain inflammation, with an increased density of microglia and macrophages, is an important component of Alzheimer’s disease (AD) and a potential therapeutic target. However, it is incompletely characterized, particularly in patients whose disease begins before the age of 65 years and, thus, have few co-pathologies. Inflammation has been usefully imaged with translocator protein (TSPO) positron emission
-
Centers for Medicare and Medicaid Services Coverage of Amyloid PET JAMA Neurol. (IF 20.4) Pub Date : 2024-07-15 Joshua D. Grill, Jennifer H. Lingler
This Viewpoint discusses the ambiguity of amyloid positron emission tomography coverage in the era of anti-amyloid therapeutics and the considerations and consequences of narrow coverage.
-
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy JAMA Neurol. (IF 20.4) Pub Date : 2024-07-15 Jason W. Adams, Daniel Kirsch, Samantha M. Calderazzo, Fatima Tuz-Zahra, Yorghos Tripodis, Jesse Mez, Michael L. Alosco, Victor E. Alvarez, Bertrand R. Huber, Caroline Kubilus, Kerry A. Cormier, Raymond Nicks, Madeline Uretsky, Evan Nair, Eva Kuzyk, Nurgul Aytan, Jonathan D. Cherry, John F. Crary, Daniel H. Daneshvar, Christopher J. Nowinski, Lee E. Goldstein, Brigid Dwyer, Douglas I. Katz, Robert
ImportanceParkinsonism is associated with traumatic brain injury and chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with repetitive head impact (RHI) exposure, but the neuropathologic substrates that underlie parkinsonism in individuals with CTE are yet to be defined.ObjectiveTo evaluate the frequency of parkinsonism in individuals with CTE and the association of RHI
-
-
The graded multidimensional geometry of phenotypic variation and progression in neurodegenerative syndromes Brain (IF 10.6) Pub Date : 2024-07-15 Siddharth Ramanan, Danyal Akarca, Shalom K Henderson, Matthew A Rouse, Kieren Allinson, Karalyn Patterson, James B Rowe, Matthew A Lambon Ralph
Clinical variants of Alzheimer’s disease and frontotemporal lobar degeneration display a spectrum of cognitive-behavioural changes varying between individuals and over time. Understanding the landscape of these graded individual-/group-level longitudinal variations is critical for precise phenotyping; however, this remains challenging to model. Addressing this challenge, we leverage the National Alzheimer’s
-
Systemic inflammatory markers in ageing, Alzheimer’s disease and other dementias Brain (IF 10.6) Pub Date : 2024-07-15 Huimin Cai, Tan Zhao, Yana Pang, Xiaofeng Fu, Ziye Ren, Shuiyue Quan, Longfei Jia
Systemic inflammation with alterations in inflammatory markers is involved in aging and Alzheimer’s disease. However, few studies have investigated the longitudinal trajectories of systemic inflammatory markers during aging and Alzheimer’s disease, and specific markers contributing to Alzheimer’s disease remain undetermined. In this study, a longitudinal cohort (cohort 1: n = 290; controls, 136; preclinical
-
Customized antisense oligonucleotide-based therapy for neurofilament-associated Charcot-Marie-Tooth disease Brain (IF 10.6) Pub Date : 2024-07-15 Jessica Medina, Adriana Rebelo, Matt C Danzi, Elizabeth H Jacobs, Isaac R L Xu, Kathleen P Ahrens, Sitong Chen, Jacquelyn Raposo, Christopher Yanick, Stephan Zuchner, Mario A Saporta
DNA-based therapeutics have emerged as a revolutionary approach for addressing the treatment gap in rare inherited conditions by targeting the fundamental genetic causes of disease. Charcot-Marie-Tooth (CMT) disease, a group of inherited neuropathies, represents one of the most prevalent Mendelian disease groups in neurology and is characterized by diverse genetic etiology. Axonal forms of CMT, known
-
Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease Mov. Disord. (IF 7.4) Pub Date : 2024-07-15 Saar Kariv, Jeong Woo Choi, Koorosh Mirpour, Ann M. Gordon, Amirreza Alijanpourotaghsara, Mohsen Benam, Ruwayd Abdalla, Sahil Chilukuri, Jianwen W. Gu, Hemant Bokil, Shruti Nanivadekar, Aryn H. Gittis, Nader Pouratian
BackgroundBurst‐patterned pallidal deep brain stimulation (DBS) in an animal model of Parkinson's disease (PD) yields significantly prolonged therapeutic benefit compared to conventional continuous DBS, but its value in patients remains unclear.ObjectivesThe aims were to evaluate the safety and tolerability of acute (<2 hours) burst DBS in PD patients and to evaluate preliminary clinical effectiveness
-
Neurochemical organization of cortical proteinopathy and neurophysiology along the Alzheimer's disease continuum Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-12 Alex I. Wiesman, Jonathan Gallego-Rudolf, Sylvia Villeneuve, Sylvain Baillet, Tony W. Wilson
Despite parallel research indicating amyloid-β accumulation, alterations in cortical neurophysiological signaling, and multi-system neurotransmitter disruptions in Alzheimer's disease (AD), the relationships between these phenomena remains unclear.
-
Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-13 Hyun Woong Roh, Nishant Chauhan, Sang Won Seo, Seong Hye Choi, Eun‐Joo Kim, Soo Hyun Cho, Byeong C. Kim, Jin Wook Choi, Young‐Sil An, Bumhee Park, Sun Min Lee, So Young Moon, You Jin Nam, Sunhwa Hong, Sang Joon Son, Chang Hyung Hong, Dongha Lee
INTRODUCTIONThis study aimed to explore the potential of whole brain white matter patterns as novel neuroimaging biomarkers for assessing cognitive impairment and disability in older adults.METHODSWe conducted an in‐depth analysis of magnetic resonance imaging (MRI) and amyloid positron emission tomography (PET) scans in 454 participants, focusing on white matter patterns and white matter inter‐subject
-
Inequalities in accelerated cognitive decline: Resolving observational window bias using nested non‐linear regression Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-13 Sean A. P. Clouston, Douglas W. Hanes, Dylan M. Smith, Lauren L. Richmond, Marcus Richards, Bruce Link
INTRODUCTIONLimited observational windows lead to conflicting results in studies examining educational differences in Alzheimer's disease and related dementias (ADRD) risk, due to observational window bias relative to onset of accelerated cognitive decline. This study tested a novel model to address observational window bias and tested for the presence and sources of disparities in accelerated cognitive
-
Synaptic mitochondria glycation contributes to mitochondrial stress and cognitive dysfunction Brain (IF 10.6) Pub Date : 2024-07-13 Sourav Samanta, Firoz Akhter, Renhao Xue, Alexandre A Sosunov, Long Wu, Doris Chen, Ottavio Arancio, Shi Fang Yan, Shirley ShiDu Yan
Mitochondrial and synaptic dysfunction are pathological features of brain aging and cognitive decline. Synaptic mitochondria are vital for meeting the high energy demands of synaptic transmission. However, little is known about the link between age-related metabolic changes and the integrity of synaptic mitochondria. To this end, we investigate the mechanisms of advanced glycation endproducts (AGEs)-mediated
-
Inflammation-induced mast cell-derived nerve growth factor: a key player in chronic vulvar pain? Brain (IF 10.6) Pub Date : 2024-07-13 Yaseen Awad-Igbaria, Doron Edelman, Elvira Ianshin, Saher Abu-Ata, Alon Shamir, Jacob Bornstein, Eilam Palzur
Provoked vulvodynia (PV) is characterized by localized chronic vulvar pain. It is associated with a history of recurrent inflammation, mast cell (MC) accumulation, and neuronal sprouting in the vulva. However, the mechanism of how vulvar-inflammation promotes neuronal sprouting and gene-expression adaptation in the spinal cord, leading to hypersensitivity and painful sensations, is unknown. Here, we
-
Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder Mov. Disord. (IF 7.4) Pub Date : 2024-07-13 Vojtěch Illner, Michal Novotný, Tomáš Kouba, Tereza Tykalová, Michal Šimek, Pavel Sovka, Jan Švihlík, Evžen Růžička, Karel Šonka, Petr Dušek, Jan Rusz
BackgroundSpeech dysfunction represents one of the initial motor manifestations to develop in Parkinson's disease (PD) and is measurable through smartphone.ObjectiveThe aim was to develop a fully automated and noise‐resistant smartphone‐based system that can unobtrusively screen for prodromal parkinsonian speech disorder in subjects with isolated rapid eye movement sleep behavior disorder (iRBD) in
-
DNA methylation patterns in the frontal lobe white matter of multiple system atrophy, Parkinson’s disease, and progressive supranuclear palsy: a cross-comparative investigation Acta Neuropathol. (IF 9.3) Pub Date : 2024-07-12 Megha Murthy, Katherine Fodder, Yasuo Miki, Naiomi Rambarack, Eduardo De Pablo Fernandez, Lasse Pihlstrøm, Jonathan Mill, Thomas T. Warner, Tammaryn Lashley, Conceição Bettencourt
-
Environmental–genetic interactions in ageing and dementia across Latin America Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-07-12 Agustin Ibanez, Andrea Slachevsky
-
The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells Mol. Neurodegener. (IF 14.9) Pub Date : 2024-07-12 Omri Zveik, Ariel Rechtman, Tal Ganz, Adi Vaknin-Dembinsky
Multiple sclerosis (MS) therapeutic goals have traditionally been dichotomized into two distinct avenues: immune-modulatory-centric interventions and pro-regenerative strategies. Oligodendrocyte progenitor cells (OPCs) were regarded for many years solely in concern to their potential to generate oligodendrocytes and myelin in the central nervous system (CNS). However, accumulating data elucidate the
-
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress Mol. Neurodegener. (IF 14.9) Pub Date : 2024-07-12 Ken Uekawa, Yorito Hattori, Sung Ji Ahn, James Seo, Nicole Casey, Antoine Anfray, Ping Zhou, Wenjie Luo, Josef Anrather, Laibaik Park, Costantino Iadecola
Correction: Molecular Neurodegeneration (2023) 18:73 https://doi.org/10.1186/s13024-023-00660-1 The original article contains a typo in the first sentence of the Neocortex sub-section of the Materials and Methods section. The concentration should instead state ‘100 µmol/L’ instead of ‘100 mmol/L’ Authors and Affiliations Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York
-
Tau‐mediated synaptic dysfunction is coupled with HCN channelopathy Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-12 Despoina Goniotaki, Francesco Tamagnini, Luca Biasetti, Svenja‐Lotta Rumpf, Claire Troakes, Saskia J. Pollack, Shalom Ukwesa, Haoyue Sun, Igor Kraev, Louise C. Serpell, Wendy Noble, Kevin Staras, Diane P. Hanger
INTRODUCTIONIn tauopathies, altered tau processing correlates with impairments in synaptic density and function. Changes in hyperpolarization‐activated cyclic nucleotide‐gated (HCN) channels contribute to disease‐associated abnormalities in multiple neurodegenerative diseases.METHODSTo investigate the link between tau and HCN channels, we performed histological, biochemical, ultrastructural, and functional
-
Cerebral arteriolosclerosis, lacunar infarcts, and cognition in older Black adults Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-11 Debra A. Fleischman, Konstantinos Arfanakis, Sue E. Leurgans, Zoe Arvanitakis, Melissa Lamar, S. Duke Han, Victoria N. Poole, David A. Bennett, Lisa L. Barnes
INTRODUCTIONOlder Black adults are at risk of cerebral small vessel disease (CSVD), which contributes to dementia risk. Two subtypes of CSVD, arteriolosclerosis and ischemic lacunar infarcts, have been independently linked to lower cognition and higher dementia risk, but their combined effects on cognition in older Black adults are unclear.METHODSMixed models were used to examine the associations of
-
The Anne and Henry Zarrow Foundation makes second $5 million grant to Alzheimer's Association for research Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-11
The Anne and Henry Zarrow Foundation has made its second $5 million grant to the Alzheimer's Association to support the Zenith Fellows Awards. The contribution brings the Tulsa, Oklahoma–based foundation's funding of the influential research program to $10 million. “Thanks to the generous support of philanthropic partners like The Anne and Henry Zarrow Foundation and other members of the Alzheimer's
-
Spatial extent as a sensitive amyloid‐PET metric in preclinical Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-07-11 Michelle E. Farrell, Emma G. Thibault, J. Alex Becker, Julie C. Price, Brian C. Healy, Bernard J. Hanseeuw, Rachel F. Buckley, Heidi I. L. Jacobs, Aaron P. Schultz, Charles D. Chen, Reisa A. Sperling, Keith A. Johnson
INTRODUCTIONSpatial extent‐based measures of how far amyloid beta (Aβ) has spread throughout the neocortex may be more sensitive than traditional Aβ‐positron emission tomography (PET) measures of Aβ level for detecting early Aβ deposits in preclinical Alzheimer's disease (AD) and improve understanding of Aβ’s association with tau proliferation and cognitive decline.METHODSPittsburgh Compound‐B (PIB)‐PET
-
Annexin A11 mutations are associated with nuclear envelope dysfunction in vivo and in human tissue Brain (IF 10.6) Pub Date : 2024-07-11 Valentina Marchica, Luca Biasetti, Jodi Barnard, Shujing Li, Nikolas Nikolaou, Matthew P Frosch, Diane E Lucente, Mark Eldaief, Andrew King, Manolis Fanto, Claire Troakes, Corinne Houart, Bradley N Smith
Annexin A11 mutations are a rare cause of amyotrophic lateral sclerosis (ALS), wherein replicated protein variants P36R, G38R, D40G and D40Y are located in a small-alpha helix within the long, disordered N-terminus. To elucidate disease mechanisms, we characterised the phenotypes induced by a genetic loss of function (LoF) and by misexpression of G38R and D40G in vivo. Loss of Annexin A11 results in
-
Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease Brain (IF 10.6) Pub Date : 2024-07-11 Lorenzo Barba, Samir Abu-Rumeileh, Henryk Barthel, Federico Massa, Matteo Foschi, Giovanni Bellomo, Lorenzo Gaetani, Dietmar R Thal, Lucilla Parnetti, Markus Otto
Concomitant Alzheimer’s disease (AD) pathology is a frequent event in the context of Lewy body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD patients with AD copathology show an accelerated disease course, a greater risk of cognitive decline and an overall poorer prognosis. However, LBD-AD cases may show heterogeneous motor and non-motor phenotypes with higher
-
Side-effects are often a curse. Can they also be a blessing? Brain (IF 10.6) Pub Date : 2024-07-11 Katja Wiech, Helena Hartmann, Ulrike Bingel
This scientific commentary refers to ‘How side effects can improve treatment efficacy: a randomized trial’ by Schenk et al. (https://doi.org/10.1093/brain/awae132).
-
Clinical Trials in Times of War: A Testament to Human Resilience and Dedication Mov. Disord. (IF 7.4) Pub Date : 2024-07-11 Joaquim J. Ferreira, Olivier Rascol, Werner Poewe
-
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease Mov. Disord. (IF 7.4) Pub Date : 2024-07-11 Kimberly H. Wood, Rodolphe Nenert, Aya M. Miften, George W. Kent, Madison Sleyster, Raima A. Memon, Allen Joop, Jennifer Pilkington, Adeel A. Memon, Riis N. Wilson, Corina Catiul, Jerzy Szaflarski, Amy W. Amara
BackgroundThe glymphatic clearance pathway is a waste clearance system that allows for removal of soluble proteins such as amyloid β (Aβ) from the brain. Higher Aβ levels are associated with cognitive dysfunction in Parkinson's disease (PD). Diffusion tensor imaging‐along the perivascular space (DTI‐ALPS) is an imaging measure proposed to indirectly measure glymphatic function.ObjectivesEvaluate differences
-
Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune Mov. Disord. (IF 7.4) Pub Date : 2024-07-11 Samuel M. Goldman, Frances M. Weaver, Beverly Gonzalez, Kevin T. Stroupe, Lishan Cao, Kalea Colletta, Ethan G. Brown, Caroline M. Tanner
BackgroundWe recently reported an increased risk of Parkinson's disease (PD) in service members who resided at Marine Base Camp Lejeune, North Carolina, when water supplies were contaminated with trichloroethylene and other volatile organic compounds (VOCs). Prior studies suggest that environmental exposures may affect PD phenotype or progression, but this has not been reported for VOCs.ObjectiveThe